secwatch.observer — SEC 8-K summary
======================================

Issuer:     Korro Bio, Inc. (KRRO)
CIK:        0001703647
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001193125-25-277556
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 1.01, 2.02, 2.05, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Korro Bio Q3 net loss $18.1M; cuts workforce 34%; Novo collaboration paused; KRRO-110 misses functional protein target
--------------------------------------------------------------------------------

- Cash, equivalents and securities $102.5M at Sept 30, 2025; net loss $18.1M for Q3.
- Workforce reduction of ~34%; expects one-time restructuring charges of ~$2.4M in Q4 2025.
- KRRO-110 produced functional M-AAT protein but peak total AAT ~10 µM missed protective 11 µM threshold; pivoting to GalNAc construct for AATD.
- Nominated KRRO-121 for hyperammonemia; first-in-human filing anticipated H2 2026.
- Novo Nordisk collaboration paused for 12 months; CMO Dr. Olugemo resigned effective Nov 12.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703647/000119312525277556/0001193125-25-277556-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703647/000119312525277556/krro-20251107.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-277556

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer